Drug General Information
Drug ID
D0L4AI
Former ID
DNC000532
Drug Name
Delta(9)-tetrahydrocannabinol
Drug Type
Small molecular drug
Indication Discovery agent Investigative [539554]
Structure
Download
2D MOL

3D MOL

Formula
C21H30O2
InChI
InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1
InChIKey
CYQFCXCEBYINGO-IAGOWNOFSA-N
CAS Number
CAS 26514
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
A04AD10
SuperDrug CAS ID
cas=001972083
Target and Pathway
Target(s) Cannabinoid receptor 1 Target Info Agonist [537149]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
BDNF signaling pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 539554(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2424).
Ref 537149Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.